Alex Blyth

Alex Blyth has an extensive background in the biotech and healthcare industries. In 2016, they founded LIfT BioSciences with the goal of developing a cell therapy to destroy solid tumors. As the CEO, they focus on building a cell bank of immuno-modulating alpha neutrophils for infusion into patients. In 2018, they also founded NGX (Nutri-Genetix) and developed a genetically personalized meal-shake called BodyFuel.

In 2022, Alex co-founded ReWire Therapeutics, where they patented a new type of oral delivery combination platform for mental health and wellness. The company aims to develop an integrated solution using personalized medicine, community, and psychoactive drugs.

Alex is also the founder and managing partner of The Mission Fund, a fund dedicated to accelerating breakthrough therapies with potentially curative outcomes. Furthermore, they are the founder of Fast-Track Ventures Ltd, a health and technology incubator for socially minded businesses.

Prior to their entrepreneurial ventures, Alex held various roles in strategic consulting and marketing sciences. Alex served as the Vice President of Cello Health Consulting, where they focused on developing asset development, launch, and uplift strategies for pharma, biotech, and medical devices. Alex was also the founder of CELLO Business Sciences, where they developed seamless marketing tools for healthcare brands.

Earlier in their career, Alex worked as the Head of Marketing Sciences at The MSI Consultancy and as a Strategy Consultant at Pope Woodhead & Associates Ltd. Alex also built a new area of business in Medical Technologies as the Head of Medical Technologies for Cambridge Consultants.

Throughout their career, Alex has demonstrated a passion for developing innovative solutions in the biotech and healthcare sectors.

Alex Blyth's education history begins with a Bachelor of Science (BSc) degree in Economics from the University of Southampton, which was obtained between 1996 and 1999. Following this, Alex pursued a Bachelor of Science (BSc) degree in Biological Sciences from The Open University, which was completed from 2002 to 2004.

In 2014, Alex attended the University of Oxford - Said Business School, where they focused on Valuation as their field of study. During this time, Alex also obtained additional certification in the Oxford Chicago Valuation Programme from the Saïd Business School at the University of Oxford in November 2014. No specific degree was mentioned for this program.